Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
出版年份 2022 全文链接
标题
Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
作者
关键词
-
出版物
JOURNAL OF GASTROENTEROLOGY
Volume 57, Issue 5, Pages 357-371
出版商
Springer Science and Business Media LLC
发表日期
2022-03-25
DOI
10.1007/s00535-022-01860-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatments for NAFLD: State of Art
- (2021) Alessandro Mantovani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside
- (2021) Don C. Rockey et al. GASTROENTEROLOGY
- Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy‐proven nonalcoholic fatty liver disease subjects
- (2021) Javier Ampuero et al. LIVER INTERNATIONAL
- Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
- (2021) Abdul M. Majzoub et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- NAFLD and Alcohol‐Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040
- (2021) Jennifer A. Flemming et al. HEPATOLOGY
- Safety and Efficacy of Biological Therapy in Chronic Antibiotic Refractory Pouchitis
- (2021) Saurabh Chandan et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Profiles of liver fibrosis evolution during long‐term tenofovir treatment in HIV‐positive patients coinfected with hepatitis B
- (2021) Lorenza N. C. Dezanet et al. LIVER INTERNATIONAL
- New drugs for NASH
- (2021) Somaya A. M. Albhaisi et al. LIVER INTERNATIONAL
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
- (2021) Marco Arrese et al. SEMINARS IN LIVER DISEASE
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
- (2020) Javier Ampuero et al. JOURNAL OF HEPATOLOGY
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
- (2020) Philip N. Newsome et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
- (2020) Anna Roskilly et al. LIVER INTERNATIONAL
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE
- (2019) Edouard Bardou-Jacquet et al. Clinical Gastroenterology and Hepatology
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
- (2019) Naga Chalasani et al. GASTROENTEROLOGY
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
- (2018) Ma Ai Thanda Han et al. Clinical Gastroenterology and Hepatology
- Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica
- (2018) Javier Ampuero et al. Gastroenterologia y Hepatologia
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease
- (2018) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention
- (2016) Eduardo Vilar-Gomez et al. HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More